Theravance Biopharma (TBPH) reported fourth-quarter 2024 adjusted net loss of 5 cents per share, which came in line with the Zacks Consensus Estimate. In the year-ago quarter, the company had recorded earnings of 3 cents per share.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The reported loss excludes share-based compensation expense, income tax expense and non-cash interest expense. Including these items, the company incurred a loss of 31 cents per share in the fourth quarter comp ...